No Data
No Data
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
NurExone Biologic Inc. Initiated at Buy by Fundamental Research
NurExone Biologic Inc. Price Target Announced at C$2.61/Share by Fundamental Research
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
NurExone's ExoPTEN, Loaded With SiRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer